Collegium Pharmaceutical, Inc. will ring the Nasdaq opening bell on October 14, 2025, to celebrate its 10-year anniversary as a publicly traded company. The company has focused on improving the lives of patients with serious medical conditions and recently expanded into neuropsychiatry with the acquisition of Jornay PM for ADHD. Jornay PM is now the fastest-growing stimulant medicine for ADHD. Collegium is poised for continued growth and making a positive impact on patient lives. The live stream of the bell ringing ceremony will be available at Nasdaq’s website.

Collegium Pharmaceutical, Inc. is a biopharmaceutical company based in Stoughton, Massachusetts, committed to improving the lives of people with serious medical conditions. They have a portfolio of responsible pain management medications and a growing neuropsychiatry business centered around Jornay PM, a treatment for ADHD. The company’s strategy includes expanding its commercial portfolio and making disciplined capital investments. Collegium is focused on growth and innovation to serve patients effectively. For more information, visit their website.

Read more at GlobeNewswire: Collegium to Celebrate 10-Year Anniversary with Nasdaq